
NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target
NRX Pharmaceuticals (NRXP) Analyst Ratings
Bulls say
NRX Pharmaceuticals Inc has bolstered its financial standing through recent financing activities, which have strengthened its cash position and facilitated ongoing development efforts in its therapeutic initiatives. The company is poised to achieve profitability on a run-rate basis by the end of 2025, supported by a robust clinical pipeline and expansion of its HOPE Therapeutics platform, which is anticipated to generate approximately $10 million in annual revenue from upcoming acquisitions. Additionally, positive clinical trial outcomes for NRX-101 enhance the company's outlook, potentially placing it as a leading treatment option for bipolar depression associated with acute suicidality, thereby reinforcing the company's target of achieving $100 million in revenue by 2025.
Bears say
NRX Pharmaceuticals Inc. is aiming to reduce its operating loss for 2024 to $18.5 million from the previous year's loss of $27.8 million, primarily through decreased research and development expenditures following the completion of the Phase 2b/3 study of NRX-101. The company faces significant risks, including the potential failure of clinical trials, the necessity for further regulatory studies, and challenges in its commercialization strategy that could hinder product launches and competitive positioning. Additionally, concerns about intellectual property, market conditions for fundraising, and the overall viability of its therapeutic developments contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction
Start investing in NRX Pharmaceuticals (NRXP)
Order type
Buy in
Order amount
Est. shares
0 shares